Kim, Won-Keun ORCID: 0000-0002-0799-7478, Thiele, Holger, Linke, Axel, Kuntze, Thomas, Fichtlscherer, Stephan, Webb, John, Chu, Michael W. A., Adam, Matti, Schymik, Gerhard, Geisler, Tobias, Kharbanda, Rajesh, Christen, Thomas and Allocco, Dominic (2022). Transcatheter Aortic Valve Implantation with ACURATE neo: Results from the PROGRESS PVL Registry. J. Interv. Cardiol., 2022. LONDON: WILEY-HINDAWI. ISSN 1540-8183

Full text not available from this repository.

Abstract

Objectives. The PROGRESS PVL registry evaluated transcatheter aortic valve implantation (TAVI) in patients treated with ACURATE neo, a supra-annular self-expanding bioprosthetic aortic valve. Background. While clinical outcomes with TAVI are comparable with those achieved with surgery, residual aortic regurgitation (AR) and paravalvular leak (PVL) are common complications. The ACURATE neo valve has a pericardial sealing skirt designed to minimize PVL. Methods. The primary endpoint was the rate of total AR over time, as assessed by a core echocardiographic laboratory. The study enrolled 500 patients (mean age: 81.8 +/- 5.1 years; 61% female; mean baseline STS score: 6.0 +/- 4.5%) from 22 centers in Europe and Canada; 498 patients were treated with ACURATE neo. Results. The rate of >= moderate AR was 4.6% at discharge and 3.1% at 12 months; the rate of >= moderate PVL was 4.6% at discharge and 2.6% at 12 months. Paired analyses showed significant improvement in overall PVL between discharge and 12 months (P < 0.001); 64.6% of patients had no change in PVL grade, 24.9% improved, and 10.5% worsened. Patients also exhibited significant improvement in transvalvular gradient (P < 0.001) and effective orifice area (P=0.01). The mortality rate was 2.2% at 30 days and 11.3% at 12 months. The permanent pacemaker implantation (PPI) rate was 10.2% at 30 days and 12.2% at 12 months. Conclusions. Results from PROGRESS PVL support the sustained safety and performance of TAVI with the ACURATE neo valve, showing excellent valve hemodynamics, good clinical outcomes, and significant interindividual improvement in PVL from discharge to 12-month follow-up.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Kim, Won-KeunUNSPECIFIEDorcid.org/0000-0002-0799-7478UNSPECIFIED
Thiele, HolgerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Linke, AxelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuntze, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fichtlscherer, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Webb, JohnUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chu, Michael W. A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Adam, MattiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schymik, GerhardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Geisler, TobiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kharbanda, RajeshUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Christen, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Allocco, DominicUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-694350
DOI: 10.1155/2022/9138403
Journal or Publication Title: J. Interv. Cardiol.
Volume: 2022
Date: 2022
Publisher: WILEY-HINDAWI
Place of Publication: LONDON
ISSN: 1540-8183
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
PARAVALVULAR REGURGITATION; 1-YEAR OUTCOMES; HEART-VALVE; REPLACEMENT; STENOSIS; IMPACT; RISK; EXPERIENCE; LEAKAGEMultiple languages
Cardiac & Cardiovascular SystemsMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69435

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item